S V Otton

Inhibition by fluoxetine of cytochrome P450 2D6 activity

S V Otton, Dafang Wu, Russell T. Joffe et al. · Clinical Pharmacology & Therapeutics · 1993 · 260 citations

Medicine, Pharmacology, Pharmacotherapy +17

Venlafaxine oxidation<i>in vitro</i>is catalysed by CYP2D6

S V Otton, S. Ball, Siu Wah Cheung et al. · British Journal of Clinical Pharmacology · 1996 · 229 citations

Medicine, Pharmacokinetics, Pharmacology +16

Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs

S V Otton, T. Inaba, W. Kalow · Life Sciences · 1984 · 187 citations

Medicine, Medicinal Chemistry, Pharmacology +13

CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone

S V Otton, Mordecai Schadel, Siu Wah Cheung et al. · Clinical Pharmacology & Therapeutics · 1993 · 182 citations

Medicine, Pharmacokinetics, Pharmacology +17

Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.

S V Otton, H.K. Crewe, M. S. Lennard et al. · Journal of Pharmacology and Experimental Therapeutics · 1988 · 163 citations

Medicine, Biochemistry, Pharmacology +17